Why United Therapeutics Corporation (UTHR) stock moved
United Therapeutics Corporation (UTHR) shares climbed 12.5% to $541.89 as of September 30, 2026, a sharp gain from the prior close of $481.47. BestStocks flagged the session as a major change for UTHR. Below, we break down what changed for UTHR, why it matters for investors, how the stock reacted, and the catalysts on the calendar.
UTHR climbed 12.5% to $541.89
United Therapeutics surged +14.51% to $551.32 after a federal court ruled unfavorably against competitor Liquidia Corp in a patent dispute over the rival pulmonary hypertension drug Yutrepia, reducing competitive pressure on UTHR's Tyvaso franchise (web_catalyst via Google AI Overview). Volume reached 1.85M shares, 4.87x the time-adjusted average, signaling strong conviction behind the move. UTHR earnings on 2026-11-04 (consensus EPS $6.46); monitor Liquidia's next steps in the patent dispute and any appeals.
What it means for United Therapeutics Corporation investors
For United Therapeutics Corporation investors, the balance of recent signals points to a bullish shift. On the constructive side: Material positive event; Strong 12.5% price move with conviction. Weighing against that: New SEC filing — review for material disclosures; New SEC filing — review for material disclosures. Wall Street's consensus price target sits at $567.75, implying +4.8% upside from $541.89. BestStocks rates the overall signal quality medium (75/100). With earnings roughly 35 days out, the next report is the most likely near-term test of the move.
UTHR price reaction
UTHR last traded at $541.89, up $60.42 (+12.55%) from the previous close of $481.47. The session traded on 5.9× average volume (extreme), so the move carried above-average conviction. Over the past month the stock has ranged between $472.21 and $541.89, and it currently sits about 100% of the way up that band.
Bullish and bearish analyst opinions on United Therapeutics Corporation (UTHR)
The consensus analyst price target on United Therapeutics Corporation (UTHR) is $567.75, 4.8% above the recent $541.89. Over the past 90 days analysts logged 0 upgrades, 4 maintains, and 0 downgrades. Here is how the bullish and bearish cases on UTHR line up.
The bullish case
- Wall Street's consensus price target of $567.75 implies +4.8% upside from $541.89.
- The Street's most bullish target is $735.00 (+35.6%).
- Material positive event.
- Strong 12.5% price move with conviction.
- Volume 5.9x average — institutional conviction.
The bearish case
- The most bearish analyst target is $321.00 (-40.8%).
- United Therapeutics Corporation (UTHR) moved -2.10% from $547.06 to $535.57 on 2026-07-13, reaching a new 30-day low.
Weighing both sides, BestStocks' composite read of recent signals is bullish, as the bull-versus-bear meter above shows. This is an educational summary of the bull and bear case, not investment advice.
Analyst price targets and ratings are FMP consensus figures as of Sep 30, 2026; other aggregators may differ. High and low targets show the range of estimates, not forecasts.
Previous notable changes for UTHR
In-depth UTHR event analyses
Frequently asked questions about UTHR
Why did United Therapeutics Corporation (UTHR) stock move?
UTHR climbed 12.5% to $541.89. The move coincided with the context summarized above, though no single company-specific catalyst was independently confirmed.
How much did UTHR stock rise?
UTHR gained 12.55% ($60.42) versus the prior close of $481.47, last trading at $541.89 on 5.9× average volume.
When is United Therapeutics Corporation's next earnings date?
UTHR's next earnings report is estimated for 2026-11-04 — about 35 days away.
What is the analyst price target for UTHR?
The consensus analyst price target for UTHR is $567.75, about 4.8% above the current $541.89. Over the past 90 days, analysts recorded 0 upgrades, 4 maintains, and 0 downgrades.
How BestStocks tracks UTHR
This page is generated automatically by BestStocks' change-detection system after its price and volume cleared UTHR-specific materiality thresholds, triggering an evidence check. It draws on 20 tracked change events for UTHR, cross-checked against the data sources listed below. Price, volume, and market-capitalization figures are the live intraday quote as of September 30, 2026 and refresh as new information is detected; for companies with multiple share classes, market-cap figures can differ by data source. Analyst price targets and ratings are FMP consensus. This is an educational summary of what changed and why — not personalized investment advice.